Fig 3.
Diagnostic sensitivity of 20 novel peptides predicted in silico in this study in groups of human serum samples (A) from patients with acute toxoplasmosis (n = 21), (B) from patients with nonactive ocular toxoplasmosis (OT patients) (n = 10), (C) from patients with latent toxoplasmosis (n = 53), and (D) from serologically positive forest workers (n = 100).